Propofol Based Tiva Vs. Sevoflurane Inhalation Anesthetic for Breast Cancer Surgery: A Systematic Review by Conte, Jacqueline Elizabeth
Rhode Island College 
Digital Commons @ RIC 
Master's Theses, Dissertations, Graduate 
Research and Major Papers Overview 
Master's Theses, Dissertations, Graduate 
Research and Major Papers 
2020 
Propofol Based Tiva Vs. Sevoflurane Inhalation Anesthetic for 
Breast Cancer Surgery: A Systematic Review 
Jacqueline Elizabeth Conte 
Follow this and additional works at: https://digitalcommons.ric.edu/etd 
 Part of the Nursing Commons 
Recommended Citation 
Conte, Jacqueline Elizabeth, "Propofol Based Tiva Vs. Sevoflurane Inhalation Anesthetic for Breast Cancer 
Surgery: A Systematic Review" (2020). Master's Theses, Dissertations, Graduate Research and Major 
Papers Overview. 348. 
https://digitalcommons.ric.edu/etd/348 
This Major Paper is brought to you for free and open access by the Master's Theses, Dissertations, Graduate 
Research and Major Papers at Digital Commons @ RIC. It has been accepted for inclusion in Master's Theses, 
Dissertations, Graduate Research and Major Papers Overview by an authorized administrator of Digital Commons 







PROPOFOL BASED TIVA VS. SEVOFLURANE INHALATION ANESTHETIC FOR 
BREAST CANCER SURGERY: A SYSTEMATIC REVIEW 
by 
Jacqueline Elizabeth Conte, RN BSN 
A Major Paper Submitted in Partial Fulfillment 
of the Requirements for the Degree of  
Master of Science in Nursing 
in 
The School of Nursing 











Metastasis from breast cancer leads to a higher chance of death from that cancer. 
According to the National Cancer Institute (2018) breast cancer survival rates among all 
three SEER stages (localized, regional, and distant) was approximately 90% between the 
years 2008 and 2014. Among these patients, those with distant metastasis had a survival 
rate of 27% and those with regional metastasis had an 85% survival rate (American 
Cancer Society, 2019). When creating an individualized anesthetic plan for a patient 
presenting for tumor excision of breast cancer, the anesthesia provider should create a 
plan that lowers the risk of metastasis and increases the patient’s chance of survival. The 
purpose of this systematic review was to analyze which anesthetic technique, Propofol 
based total Intravenous Anesthesia (TIVA) or Sevoflurane based inhalation anesthetic, 
will elicit less immune response. A comprehensive literature review was completed using 
CINAHL, Medline Plus, and Pubmed Health focusing on propofol based TIVA and 
Sevoflurane for anesthesia maintenance for the removal of cancerous breast tumors. The 
PRISMA model was used to identify eligible studies. Study analysis was completed by 
creating study specific and data outcome tables. Critical appraisal of individual 
randomized control trials was performed using the Critical Appraisal Skills Programme 
(CASP) checklist. A cross study analysis table was also created to compare the results of 
all eligible studies. The findings of this systematic review determined that Propofol based 
TIVA increases recurrence free survival, however there is negligible differences in the 
immune response between Propofol based TIVA and Sevoflurane inhalation anesthetic 
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Propofol Based TIVA Vs. Sevoflurane Inhalation Anesthetic for Breast Cancer Surgery: A 
Systematic Review 
Background/Statement of the Problem 
Treatment of choice for many solid tumor cancers is excision of the tumor via 
surgery (Anand et al. 2015). Anesthesia plays an important role in the success, comfort, 
and overall surgical experience for the patient. The anesthesia provider should form an 
anesthetic plan that factors in the physiologic and pathophysiologic conditions of the 
specific patient (Nagelhout & Plaus, 2016). There is much debate about which type of 
anesthesia is best for patients undergoing surgery for the excision of cancerous tumors. 
Some studies have shown that Propofol and local anesthetics are the best choice to limit 
cancer metastasis Ito et al. (2017). However, many providers still choose to use a general 
anesthetic technique that includes the use of volatile agents such as Sevoflurane.   
According to the National Cancer Institute (2018) breast cancer survival rates 
among all three SEER stages (localized, regional, and distant) is approximately 90% 
between the years 2008 and 2014. Among these patients, those with distant metastasis 
had a survival rate of 27% and those with regional metastasis had an 85% survival rate. 
This shows that the more metastasis to distant areas, the lower the chance of survival of 
the patient (American Cancer Society, 2019). When creating an individualized anesthetic 
plan for a patient presenting for tumor excision of breast cancer, the anesthesia provider 
should create a plan that lowers the risk of metastasis and increases the patient’s chance 
of survival. It is hypothesized that Total Intravenous Anesthesia (TIVA) for the 
maintenance phase of anesthesia during surgical excision of cancerous tumors of the 
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breast will limit the number of immune cells released that are related to cancer 
metastasis.  
The purpose of this study is to examine if Total Intravenous Anesthesia versus 
Sevoflurane is more efficacious in limiting the amounts of immune cells released during 
the perioperative period in breast cancer patients.  
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Literature Review 
The literature presented here will provide general background on immunity, 
immune system changes that lead to cancer metastasis, breast cancer, surgeries to excise 
breast cancer, the impact these procedures have on the immune system, and anesthetic 
choice for breast cancer surgery. Immunemodulation from anesthetic choice will also be 
explored. Data was searched from 2002-present for this review. Search databases include 
CINAHL, Medline Plus, and Pubmed Health. Additional data was sought in textbooks 
and Google scholar with relevance to the topic. 
Keywords: anesthesia, breast cancer, breast cancer surgery, immune response, 
immunosuppression, propofol, sevoflurane, TIVA, general anesthesia, volatile 
anesthetics, and survival rates.  
The aim of this project is to examine if Total Intravenous Anesthesia versus 
Sevoflurane is more efficacious in limiting the amounts of immune cells released during 
the perioperative period in breast cancer patients. This topic is relevant and valuable to 
the discussion on anesthetic choice and its impact on immune system and overall survival 
of breast cancer patients. Surgery evokes a surgical stress response and with it an immune 
response in all patients. Anesthetics also impact the immune system. Given these 
contributory factors, it is important to select an anesthetic that will provide less 





                                                                                                                                             
 
   
 




The human body is able to resist infection from organisms as well as recognize 
aberrant cell growth, through the immune system. Immunity falls into two classifications 
with some overlapping cells and processes.  
The first type of immunity is innate immunity (Guyton & Hall, 2011). Innate 
immunity has several functions. Innate immunity phacocytizes bacteria via macrophages 
and white blood cells, destroys organisms though the acid that is secreted in the stomach, 
resists invasion or organisms through the epithelial layer, and the utilization of chemical 
compounds that attach to foreign organisms and or toxins (Guyton & Hall, 2011). Cells 
that play a role in innate immunity include epithelial cells, monocytes, macrophages, 
dendritic cells, natural killer cells (NK), and leucocytes. Various lymphocyte subtypes 
help bridge innate and acquired immunity. These subtypes include CD5-positive B-
lymphocytes and gd T-lymphocytes (Guyton & Hall, 2011).  
The second type of immunity is acquired immunity. The cells involved in this 
branch of immunity are lymphocytes. This includes B-lymphocytes, T-lymphocytes, and 
natural killer cells (NK) (Eissmann, 2015). Acquired immunity works by creating genetic 
mutations on the B and T lymphocytes. These are expressed as antibodies and T cell 
receptors. When antibodies or T-cell receptors bind to antigens proliferation of antigen-
specific lymphocytes occurs. A specific immune response then ensues. Each antibody 
binds to specific antigens. This specificity allows for selective proliferation of clonal 
lymphocytes that correlate with the antigen (Guyton & Hall, 2011). 
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Other key elements include major histocompatibility complex (MHC) and 
cytokines. These allow for cell-to-cell communication that is involved in both acquired 
and innate immunity. Another component in acquired immunity is the surface protein 
CD40. When combined with its receptor a costimulatory signal for interaction between 
antigen presenting cells and T-cells (Adam et al., 2003). Between innate and acquired 
immunity there is overlap. Both types of immunity interact, and in some cases utilize cell 
types to carry out the overall function of the immune system.  
The Immune System’s Role in Neoplasia and Metastasis Development 
Cancer develops from the body’s normal cells and transitions into cancer cells 
through deranged growth. There are seven common characteristics of the transition from 
normal cells to cancerous cells. This includes the ability of cancer cells to stimulate their 
own growth, resist the immune systems efforts to halt growth, cancer cells are not subject 
to normal apoptosis, they are able signal for new blood vessel development through 
angiogenesis, they multiply indefinitely, metastasize to other sites, and invade both 
acquired and innate immune system (Malik et al. 2014).  
Once cancer cells have developed, they are able to form a primary tumor site 
known as a neoplasia. As the neoplasia develops its genetic makeup is changed to further 
aid in the development of more cancer cells and metastasis. With ongoing tumor growth, 
a normal inflammatory response is invoked, which signal for neutrophils, eosinophils, 
and monocytes to come to the tumor site. This creates an environment that is favorable 
for metastasis (Malik et al. 2014).  
Research shows that there is a link between immune system dysfunction and the 
development of cancer metastasis. As pointed out by Critchley-Thorne et al. (2009), 
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innate immune dysfunction is a common defect in cancer patients. Specifically, the 
interferon signaling pathway is impaired, which, leads to lymphocyte dysfunction in 
cancer patients. To demonstrate this, Critchley-Thorne et al. (2009), took peripheral 
blood samples from patients who had breast cancer, gastrointestinal cancer, or melanoma. 
They then analyzed the samples from these patients and looked at the amount of 
interferon signaling gene expression (ISG) (Critchley-Thorne et al., 2009). The 
researchers found that the levels of the five major ISGs, were decreased when compared 
to healthy controls: STAT1,  p = 0.0381; IFI44,  p = 0.0303; IFIT,  p = 0.0480; IFIT2, p = 
0.0177; and MX1, p = 0.019 (Critchley-Thorne et al., 2009). This is indicative of 
lymphocyte dysfunction, which, leads to a decreased immune response in cancer patients. 
This decreased response allows for immune suppression and places the patient at a higher 
risk for infection. Chrichley-Thorne et al. (2009) also measured the response to IFN-a 
and IFN-g stimulation in the peripheral blood lymphocyte samples from twenty-seven 
breast cancer patients (Critchley-Thorne et al., 2009). These patients had breast cancer 
stage two, three, and four. The researchers did the same for twelve patients with 
melanoma in stage three and four, as well as eleven patients with gastrointestinal cancer 
staged two, three, and four. These results were compared to twenty-eight aged matched 
healthy controls (Critchley-Thorne et al. 2009). The researchers found that changes in 
pSTAT1 induced by IFN-a was significantly reduced in T, B, and NK cells within all of 
the cancer types versus health controls (p < 0.05) (Critchley-Thorne et al., 2009). STAT1 
plays a vital role in the formation of proteins necessary for the immune system to 
recognize and destroy viruses via the interferon alpha/beta pathway (US National Library 
of Medicine, 2019). The researchers then extrapolated that IFN signaling is reduced in 
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early stages of cancer and remains reduced in later stages (Critchley-Thorne et al., 2009). 
Thus, leaving cancer patients vulnerable to viral infections. Further research suggested by 
Critchley-Thorne et al. (2009), at the conclusion of this study, included enhancement of 
the human immune systems as a way to resist existing neoplasia and negate metastasis. 
Since the work of researchers like Critchley-Thorne et al. (2009), immunotherapy 
has become a broad and ever-growing field. There are several types of immunotherapy 
treatments being developed as treatments for breast cancer. Vaccination as a way to get 
the immune system to recognize and attack cancer cells is one such example. For 
example, Delirezh, et al. (2016) sought to develop a vaccine to allow the immune system 
to recognize and thus attack the breast cancer cells. These researchers injected 4T1 
mammary carcinoma cells into mice and waited until a palpable tumor developed. Mice 
were then randomly placed into either a control group where they received vaccines of 
phosphate buffered saline and a vaccination group, a vaccination group with 4T1 (4T1) 
only, or a vaccination group with 4T1 and naloxone (4T1+NLX). Naloxone has been 
used in cancer studies as an adjuvant to solutions and vaccinations (Bimonte et al., 2018). 
Naloxone has been shown to decrease the proliferation of breast cancer cells of the 
estrogen receptor-negative human breast carcinoma cells strain (Bimonte et al., 2018). 
Furthermore, Naloxone has also been shown to induce cancer cell apoptosis (Bimonte et 
al., 2018).  
The vaccination groups were injected at regular intervals with heated 4T1 extract 
mixed with naloxone (Delirezh, et al., 2016), and a second ground that received 4T1 
without any additive. Tumor growth was measured throughout the injection period. The 
amount of splenocyte and cytokine release was measured after euthanasia. Splenocytes 
                                                                                                                                             
 
   
 
            8 
 
are white blood cells that come from the spleen. The reduction in splenocytes are 
indicative of a suppressed immune system (Guyton & Hall, 2011). Cytokines are peptides 
that are secreted by cells and function as signaling molecules. Examples of cytokines 
include interleukins and lymphokines (Guyton & Hall, 2011). The reduction in cytokines 
leads to less signaling and overall reduction in function of both innate and acquired 
immunity (Guyton & Hall, 2011).  
 Cytokine release IFN-g production was upregulated in the heated 4T1+NLX 
group as compared to the control group (p<0.05) (Delirezh, et al., 2016). Overall tumor 
size was also decreased in the 4T1+NLX group (p <0.05). There was also more 
phagocyte production in the 4T1+NLX group when compared to the control group 
(p<0.001). Tumor size in the 4T1 group was similar in size to the control tumor mice. 
Splenocyte proliferation was higher in the 4T1+NLX group compared to the 4T1 mice.  
Overall findings indicate that vaccination utilizing heated 4T1 with naloxone increases 
the ability of the immune system to recognize breast cancer cells, increases the amount of 
phagocytes available to destroy the cancer cells, and limits overall tumor growth 
(Delirezh, et al., 2016). 
Breast Cancer  
According to the United States Center for Disease Control and Prevention, breast 
cancer is the most common type of cancer among women of all races (Centers for 
Disease Control, 2019).  In the year 2016, there were 245,299 new cases of breast cancer 
in the United States (Centers for Disease Control, 2019). Forty-one thousand, four 
hundred eighty-seven women died of breast cancer in 2016.  The risk of getting breast 
cancer among women of all races has not increased overall in the last decade (Centers for 
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Disease Control, 2019); However, it has increased significantly among African 
Americans and Asian Americans races. Risk factors for breast cancer are both modifiable 
and nonmodifiable. Modifiable risk factors that increase the risk of breast cancer include 
sedentary lifestyle, obesity, hormone replacement post-menopause and hormone birth 
control  (Aryandono et al., 2017), reproductive history including not having a child or 
having a child over the age of 30, and alcohol intake (Centers for Disease Control, 2019) 
. Nonmodifiable risk factors include increased age, genetic mutations such as having the 
BRCA1 or BRCA2 gene, having dense breasts, family history of breast cancer 
(Aryandono et al., 2 017), and previous radiation therapy (Centers for Disease Control, 
2019).  
Early detection of breast cancer increases overall survival and usually discovered 
via mammography; however the lesion may be found by an individual during a breast 
self-exam (Norris, 2019). Diagnosis of breast cancer is done through mammography, 
ultrasonography, needle aspiration, and or excisional biopsy. Breast cancer often presents 
as a unilateral, solitary, firm, fixed, painless lesion. Usually the boarders are poorly 
defined (Norris, 2019).   
Surgical resection of tumors is considered a definitive and first line treatment for 
solid neoplasms such as breast cancer (Ben-Eliyahu & Neeman, 2013).  However, 
surgery is often associated with promotion of micrometastasis, which then allow for the 
development of new metastatic sites (Ben-Eliyahu & Neeman, 2013).  According to the 
National Cancer Institute (2019), micrometastasis are small numbers of cancer cells that 
are released and spread away from the primary tumor site; however, the amount is too 
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small to be detected on any screening or diagnostic test. If left unchecked by the immune 
system, micrometastasis leads to additional tumor sites throughout the body.  
Recenlty, Chang et al. (2019) identified a key enzyme involved with inhibition of 
the immune system in response to breast cancer. Specifically, the immune system’s 
ability to upregulate the amount of CD8+ T cells available, as well as the amount of 
immune stimulatory myeloid subsets (Chang et al., 2019). Certain types of breast cancers 
can upregulate the enzyme calcium/calmodulin-dependent kinase (CaMKK2), which 
allows for the suppression of CD8+ and immune stimulatory myeloid subsets. Once 
CD8+ and immune stimulatory subsets are inhibited, neoplasia can successfully avoid 
recognition, and ultimately destruction, by the immune system (Chang et al., 2019). 
Researchers took breast cancer samples from willing participants and extracted cells. 
Cells were then injected into murine models and samples of the tumors were collected 
(Changet al., 2019). Results revealed that CaMKK2 was present at high levels within the 
breast cancer cells, and CD8+ T cells were suppressed (p <0.05). However, when the 
researchers suppressed CaMKK2 in breast cancer cells, CD8+ T cells were then 
detectable, and resulted in tumor growth inhibition (p <0.05) (Chang et al., 2019). This 
study demonstrates that by inhibiting the CaMKK2 pathway, CD8+ cells are available to 
aid in tumor suppression and limit overall tumor cell growth.  
Surgical Procedures for Excision of Cancerous Breast Tumors.  
Historically, radical mastectomies were the surgery of choice for breast cancer. 
This surgical technique is very invasive and involves the removal of the breast and 
underlying pectoral muscles. During this procedure the axillary lymph nodes are also 
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removed. This technique has been replaced with less invasive techniques (Golianu et al., 
2018).  
There are now two primary, minimally invasive, approaches to excision of 
cancerous breast tumors. One technique spares most breast tissue. The aim of this 
approach is to remove the tumor only. This approach is termed lumpectomy. The second 
approach is removal of the breast in its entirety. This is called mastectomy (Dave et al., 
2010). Mastectomy is the technique of choice for more invasive breast cancer with 
extensive duct involvement or with a perceived high risk of metastasis. Mastectomy can 
also be done prophylactically for high risk patients. Both techniques can be accompanied 
by lymphatic mapping, sentinel node biopsy, and or axillary dissection (Golianu et al., 
2018).  
In a twenty year follow up to a randomized control trial, investigators found no 
difference in survival rates between radical mastectomy and less invasive surgical 
techniques (Cascinelli et al., 2002). From the years 1973 to 1980, 701 women with breast 
cancer tumors that measured more than 2 cm were randomly assigned to undergo either a 
radical mastectomy or less invasive quadrantectomy (Cascinelli et al., 2002). Both groups 
received radiotherapy to the ipsilateral breast tissue. There were 349 patients in the 
radical mastectomy group and 352 in the quadrantectomy group. After the year 1976 if 
patients in either group had positive axillary node involvement, they then received 
chemotherapy (Cascinelli et al., 2002). At the twenty year follow up, thirty women in the 
quadrantectomy group had tumor recurrence in the same breast while eight women had 
local recurrences in the radical mastectomy group, which is a statistically significant 
difference (p < 0.001) (Cascinelli et al., 2002). There was no significant difference 
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between the two groups in the rates of contralateral breast cancers, distant metastases, or 
secondary cancers.  
At the 20 year follow up the rate of death from all causes was found to be 41.7 
percent in the quadrantectomy group and 41.2 in the radical mastectomy group 
(Cascinelli et al., 2002). During that same time period, it was shown that there was more 
cancer recurrence and associated metastasis with less invasive techniques, such as 
lumpectomy. This is linked with the amount of micrometastasis at time of diagnosis and 
not with the surgical technique (Cascinelli et al., 2002). Overall surgery no matter what 
type, is associated with the acceleration and development of micrometastasis and the 
promotion of new metastasis.   
The processes thought to be responsible for metastasis related to surgery is the 
suppression of acquired immune cell responses. Surgery involves the manipulation of the 
neoplasm, its surrounding vasculature, and lymphatic system (Ben-Eliyahu & 
Goldfarb,2007). During the perioperative period, natural killer cell suppression and 
upregulation of proangiogenic  factors such as VEGF, allow for micrometastasis to not 
only evade recognition, and stop the metastatic cells from being phagocytized, but allow 
for easy invasion to other areas (Ben-Eliyahu & Goldfarb, 2007). Although the 
pathophysiology behind natural killer cell activity suppression after surgery is still not 
completely understood, it has been shown to be suppressed within hours of the surgery, 
and has been shown to last for several days postoperatively (Ben-Eliyahu & Goldfarb, 
2007). There are several proposed mechanisms that could explain the decrease in NK cell 
cytotoxicity post-surgery. According to Lotzva et al. (1991), NK cell cytotoxic 
impairment is caused by a “toxic” effect. This is caused by the surge of catecholamines, 
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glucocorticoids, and prostaglandins from surgery. Together these substances have been 
shown to suppress NK cell activity (Lotzva et al., 1991). A study by Angka et al. (2017), 
linked the inflammatory response, specifically the increased amount of IL-6 production 
during both the acute proinflammatory phase and the prolonged anti-inflammatory phase, 
with NK cell suppression and cytotoxicity.   
The deleterious effects associated with surgery are mediated through several 
mechanisms. This includes the surgical stress response that is mediated by 
neuroendocrine and metabolic responses (Buggy et al., 2006). These responses lead to a 
transient inhibition of the immune system, which allows for the cancer cells to further 
metastasize and develop new tumor sites (Buggy et al., 2006).  
Anesthesia Plans for Breast Cancer Tumor Excision 
Anesthetic plans are determined on an individual basis and are decided upon due 
to the patient’s pathophysiologic conditions, physical limitations, adverse medication 
reactions, and creating optimal surgical conditions. However, some generalizations can 
be made. In the case of breast cancer tumor excision, the decision to use one technique 
over the other is based on many factors including anesthetic provider preference, surgeon 
preference, the patients’ physiologic state, and type of procedure being performed 
(Nagelhout & Plaus, 2016). General anesthesia is always used, although the type of 
general anesthetic may vary. Sometimes providers may utilize regional techniques, such 
as paravertebral blocks, to provide more postoperative pain relief (Golianu et al., 2018). 
General anesthesia: Volatile agent Sevoflurane. General anesthesia consists of 
insertion of an advanced airway, such as laryngeal mask airway or endotracheal tube 
(Nagelhout & Plaus, 2016). his allows the provider to ventilate the patient and administer 
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volatile anesthetic agents (Nagelhout & Plaus, 2016). Volatile agents allow for the patient 
to be placed in stage three of general anesthesia (Nagelhout & Plaus, 2016).  In this stage 
patients will not respond to noxious stimuli such as a surgical incision (Nagelhout & 
Plaus, 2016). There are several volatile agents used in practice today to achieve this depth 
of anesthesia. One of the most commonly used agents is Sevoflurane (Nagelhout & Plaus, 
2016).  
Sevoflurane is a newer inhaled anesthetic that was discovered in the late 1960s 
and began to be commonly used in the 1990s. Advantages of sevoflurane include rapid 
uptake and elimination. It has good bronchodilating properties that make it appropriate 
for use in asthmatics and to lessen the risk of bronchospasm during induction, 
maintenance, and emergence phases of anesthesia. The cardiovascular effects are similar 
to that of an older volatile agent isoflurane. It provides good heart rate stability with 
slight reductions in cardiac output. Like all volatile agents, it provides dose dependent 
reductions in systemic vascular resistance and mean arteriolar pressures (Nagelhout & 
Plaus, 2016). 
There are some disadvantages specific to sevoflurane. It is highly reactive with 
the desiccated carbon dioxide absorbent soda lime. When used with desiccated 
absorbents, sevoflurane has been linked with machine fires and patient injury. A second 
disadvantage is that it has been shown to cause renal failure in murine studies. This was 
attributed to Compound A formation when sevoflurane was administered with fresh gas 
flow rates less than two liters per minute (Nagelhout & Plaus, 2016). 
All volatile anesthetic agents suppress all components of the immune system. This 
includes acquired and innate immune system components. The amount and which 
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specific cells are suppressed, depend on the agent used (Benzonana et al., 2011). 
Specifically, Sevoflurane has been shown to decrease the number of neutrophils, 
macrophages, T lymphocytes, and B lymphocytes (Dou et al., 2016). Sevoflurane has 
also been shown to reduce the cytotoxicity of NK cells (Dou et al., 2016).  
A study done by Buggy et al. (2013), which utilized in vitro models, demonstrated 
increased breast cancer proliferation and metastasis with the use of Sevoflurane. Two 
types of breast cancer cells were utilized for this study, MCF7 ER+, which is estrogen 
receptor negative human breast adenocarcinoma, and MDA-MB-231 ER-, estrogen and 
progesterone receptor-positive human breast adenocarcinoma (Buggy et al., 2013). Both 
types of cells were incubated with or without Sevoflurane at concentrations of 1, 2, 3, and 
4 mM for six hours. The researchers utilized cell proliferation migration and invasion 
assays to measure the effects of the Sevoflurane on the breast cancer cells. An 
independent t-test analysis compared for differences between the Sevoflurane and non-
Sevoflurane groups. Sevoflurane increased proliferation of MCF7 cells by 50-60% 
(Buggy et al., 2013). Sevoflurane was also found to increase proliferation of MDA-MB-
231 cells by 50-67% (p<0.05) (Buggy et al., 2013). Sevoflurane increased migration by 
30-58% in the MCF7 (p = 0.04) and 30-230% in the MDA-MB-231 group (Buggy et al., 
2013). Invasion ranged from 100-170% in MCF-7 (p = 0.02) and 28-72% in the MDA-
MB-231 group, with statistical significance at the 4 mM concentration (Buggy et al., 
2013). This study demonstrates that Sevoflurane inhalation anesthetic creates a 
proliferation of breast cancer cells, thus is not the ideal choice for breast cancer surgery.  
Total intravenous anesthesia. Total Intravenous Anesthesia (TIVA) is the 
maintenance of anesthesia using intravenous medications only. No inhalation agents are 
                                                                                                                                             
 
   
 
            16 
 
used for the maintenance phase of the anesthetic. The most common indication for TIVA 
is if the patient has a known history of malignant hyperthermia or has a risk for malignant 
hyperthermia. Some less common indications include long QT syndrome, surgery 
requiring neurophysiological monitoring, and Myesthenia Gravis and other neurological 
disorders to avoid neuromuscular blocking agents (Al-Rifai & Mulvey, 2016).  
Commonly propofol is used as the agent of choice for TIVA. It provides good hypnosis, 
amnesia, and has some level of antiemetic effect. Propofol can also be used in 
conjunction with the opioid Remifentanil to provide adequate pain management and 
synergistic sedation for the maintenance phase of the anesthetic (Nagelhout & Plaus, 
2018). Propofol does not impair the function of NK cells like Sevoflurane does (Dilger, 
2018). Propofol has also been shown to have better long-term survival rates when 
compared to volatile agents such as Sevoflurane (Jhanji et al., 2016). 
In addition to the above listed benefits, propofol has been shown to aid in the 
infiltration of cancerous tumors with the body’s own NK cells and T lymphocytes 
(Buggy et al., 2015). In a follow-up pilot study done by Buggy et al., (2015), ethics 
committee approval was given to contact patients currently involved in another breast 
cancer study. Thirty women who were already randomized into another clinical trial were 
contacted and consented to have their breast tissue reviewed and re-stained for 
immunocyte infiltration. Participants were randomized into two anesthetic groups: 
Propofol-paravertebral anesthesia (PPA, n=12) or general anesthesia with opioid 
analgesia (GA, n=16) (Buggy et al., 2015). The amount of infiltration was measured via 
the amount of CD4 (T Helper cells), CD8 (T suppressor cells), CD56 (NK cells) and 
CD68 (macrophages) cells that were present in the sample after staining (Buggy et al., 
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2015).  The normalized positive intensity values (median and interquartile range IRQ) 
showed that CD56 (NK cells) was lower in the GA group 121 versus the PPA group 136 
(p = 0.015). The CD4 (T Helper cells) cell count was also lower in the GA group 10.9 
(5.5-27.8) versus PPA 19.7 (14.4-83.5) (p = 0.03) (Buggy et al., 2015).  This 
demonstrated that there is more infiltration by NK cells as well as T helper cell into 
breast cancer samples, as the overall number of NK cells and T helper cells present in the 
stained tissue was higher. If there are more NK cells present to mount an immune 
response against the cancer cells there will be less metastasis.  
In murine models propofol has further been shown to suppress some NK activity 
but lead to less metastasis when compared to thiopental, ketamine, and halothane (Bar-
Yosef, et al., 2003). In a study of 344 anesthetized rats, subjects were anesthetized for 
one hour with either: ketamine, thiopental, halothane, or propofol (Bar-Yosef, et al., 
2003). The rats were then injected with breast cancer, specifically MADB106, tumor 
cells (Bar-Yosef, et al., 2003). At the twenty-four hour mark the amount of lung 
metastasis was counted. A second count of metastasis was made at the three-week mark. 
The researchers also counted the amount of circulating NK cells right after anesthesia. 
Propofol caused a 23.5% reduction in NK cells whereas thiopental had an NK reduction 
of 55.13%, which was the largest NK reduction among the selected agents (Bar-Yosef, et 
al., 2003). Ketamine demonstrated the highest amount of lung metastasis whereas 
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Sevoflurane Versus TIVA for Surgical Excision of Breast Cancer 
Several studies have examined the connection between cancer, immunity, and 
metastasis. For example, according to Ah et al. (2016) propofol independently reduces 
cancer cell migration and leads to less metastasis. This led researchers in this 
retrospective study to examine if propofol based TIVA or sevoflurane anesthesia for 
modified mastectomy would lead to better five-year survival rates. Ah et al. (2016) 
analyzed data from 363 cases. Of these, 173 patients underwent modified radical 
mastectomy with TIVA and 152 underwent modified radical mastectomy with 
sevoflurane. The findings showed that there were no differences in survival between the 
two groups. However, the TIVA group had a significantly lower cancer recurrence rate 
(11.6%) versus the sevoflurane group (19.1%) (p = 0.037) (Ah et al., 2016).  At the five-
year mark, 9 of 173 (5.2%) patient deaths occurred in the Propofol group whereas 11 out 
of 153 (7.2%) patients in the Sevoflurane group had passed away (Ah et al., 2016). 
Andreasson et al. (2014) also demonstrated that propofol was a better anesthetic 
choice for one-year survival for breast cancer patients than sevoflurane. In a retrospective 
case study, researchers examined surgical cases for patients undergoing a variety of 
surgical procedures for resection of cancer. Women who had undergone resection of 
breast cancer tumors were included, as well as patients who had undergone procedures 
for colon and rectal cancers. One thousand eight hundred and thirty-seven breast cancer 
patients were included within the study population. Although investigators found no 
overall difference in survival between sevoflurane or TIVA groups at the five-year mark, 
there were significant findings for the one-year mark. Specifically, the findings showed 
that breast cancer patients had a better survival rate at the one-year mark when TIVA had 
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been used versus sevoflurane (Andreasson et. al., 2014).  Patients that had undergone 
breast cancer surgery with sevoflurane based anesthesia had a one-year survival 
confidence interval of 0.96, whereas the propofol based TIVA group had a confidence 
interval of 0.99 at the one-year mark (Andreasson et. al., 2014). The difference in 
survival between the two groups was a confidence interval of 0.03 (0.01-0.04) (p < 0.001) 
(Andreasson et. al., 2014). In addition, the researchers looked at all surgical survival rates 
combined, and found that propofol based TIVA had a better overall survival rate (p = 
0.004) (Andreasson et. al., 2014).  
The immune system is complex and its influence on the development of breast 
cancer and metastasis is even more so. Research has shown that when the immune system 
is unable to function in its normal capacity, breast cancer is able to develop and 
eventually metastasize. Several studies have shown that the type of general anesthesia 
used for the maintenance phase of breast cancer tumor excision, either volatile agent 
Sevoflurane or TIVA, can suppress the immune system and aid in development of 
metastasis. As anesthesia providers formulate an anesthetic plan for patients undergoing 
breast cancer tumor excision, immune system optimization should be a primary goal. 
Selection of a general anesthetic should limit the amount of immune response, which in 
turn could lead to better long-term survival.  
Therefore, the purpose of this systematic review is to examine if Total 
Intravenous Anesthesia versus sevoflurane is more efficacious in limiting the amounts of 
immune cells released during the perioperative period in breast cancer patients. Relevant 
literature was explored to examine anesthetic choice and its effect on the immune system, 
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surgical advances impact on survival, and breast cancer survival rates with Sevoflurane 
and TIVA.  
Next the theoretical framework used to guide this study is presented.  
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Theoretical Framework 
A theoretical framework is utilized in research to serve as an organizational 
outline that pertains to a particular theory. The theoretical framework helps to serve 
insight into the topic of choice. It also provides strength to the research as well as gives 
reasoning as to why a particular topic requires further study.  
The theoretical framework that guided this systematic review is the Preferred 
Reporting Items for a Systematic Reviews and Meta-Analyses (PRISMA). PRISMA is 
a 27-item checklist and a flow diagram. The diagram is a four-phase diagram (Altman et 
al., 2009).  The included items are necessary for transparent reporting of a systematic 
review.  
The PRISMA checklist is divided into seven sections. These sections include 
abstract, introduction, methods, results, discussion, and findings (Altman et al., 2009). 
Each section is used to compile a thorough review of each article (Altman et al, 2009).   
The four-phase diagram is a graphic representation of the final articles used. It 
identifies the articles used, screening used, and eligibility determination. The diagrams, 
shown on page 27 and 28, also illustrate how many records were found and which 
databases were searched (Altman et al., 2009).  
Next, the methods will be discussed.  
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Figure 1. PRISMA Checklist 
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The purpose of this study is to examine if Total Intravenous Anesthesia versus 
sevoflurane is more efficacious in limiting the amounts of immune cells released during 
the perioperative period in breast cancer patients.   
Design 
 The design of this study is a systematic review of the literature.  
 
Search Strategy 
Research studies were sought through data bases including Pubmed, CINHAL, 
and Medline. Search terms included were: Sevoflurane, TIVA, breast cancer surgery, 
mastectomy, immune response, and lumpectomy. Additional literature was sought using 
Google Scholar.  
Inclusion/Exclusion Criteria 
Inclusion criteria for studies reviewed were: (a) adult females age 20-80 (b) 
female patients undergoing surgical procedures for the excision of breast cancer tumors 
(c) randomized control trials that have compared TIVA to sevoflurane as the anesthetic 
during the maintenance portion of the procedure, and (d) quantitative measurement of 
amounts, as well as identification of types of cells measured. Studies that utilized 
supplemental pain control or nerve blocks for pain management were included. Studies 
were included regardless of induction agent used. Studies including males, children, and 
females over the age of 80 years old were excluded.   
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Data Collection  
The study information collected included aim, design, site, sample, method, and 
outcomes. Outcome specific data sought included the inflammatory cell that 
was measured and patient outcomes related to amount of metastasis. The primary 
outcome variable that was collected is the amount of immune cell released in response to 
the specific type of anesthesia.   
Critical Appraisal and Cross Study Analysis  
The Critical Appraisal Skills Programme was used to appraise validity of the 
research studies analyzed. The CASP checklist is an 11question series used to determine 
if randomized control trials are appropriate to use in a systematic review. It is further 
divided into three sections. The first section is to review the validity of the study. There 
are five questions within the first section. The researcher answers the questions to help 
determine if the results of the study are valid.  The second section is to review the results 
of the study. This section contains two questions. The researcher answers each question 
to determine what the results of the study are. The last section is the application of the 
study to the population at hand. There are three questions within this section. These 
questions help to establish how the results can be applied to practice (CASP, 2017). The 
checklist, shown on page 31, in its entirety provides a concise way to evaluate each 
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The completed flow diagram, ash shown on page 31, is a visual demonstrating 
how the final five studies were chosen to implement in this systematic review. The initial 
search term “Sevoflurane” was used and resulted in 18,466 studies. Additional search 
terms including “Propofol” and “TIVA” narrowed the results to 285. Lastly, the terms 
“immune” and “breast cancer” were added and narrowed the results to 5 studies. There 
were no duplicate articles to exclude from this systematic review. After article screening, 
none were excluded, as all of the five studies met inclusion criteria previously identified. 
The remaining five articles were selected to complete this systematic review to determine 
if total intravenous anesthesia versus Sevoflurane is more efficacious in limiting the 
amounts of immune cells released during the perioperative period in breast cancer 
patients.  
Each of the studies reviewed for this systematic review have an explanation of the 
results with the study findings clearly identified. Study specific data is shown in 
Appendix A (Tables A1-A5). Information obtained for these tables include the study 
design, purpose, location, sample size, and methods. Outcome data collection tables were 
created to summarize the results of those studies. The tables are included in Appendix B 
(Tables B1-B5). Specific findings include what types of immune cells were studied and 
amounts of cells released in identified time intervals. Critical appraisal data tables 
(Appendix C, Tables C1-C5) were used to assess the validity, reliability, and applicability 
of the studies included in this systematic review. Lastly, a cross-study analysis data table 
was used (Appendix D) comparing the results of each study.  
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Individual Studies  
 The single-center, randomized, parallel group study by Yan et al. (2018) 
(Appendix A, Table A-1) examined the effects of Propofol based TIVA and Sevoflurane 
anesthetic on proangiogenic factors and further evaluated for a correlation between 
proangiogenic factors released in occurrence free survival in breast cancer patients. A 
total of 83 patients who underwent breast cancer surgery, specifically modified radical 
mastectomy or breast conserving surgery, were divided into two groups. Group 1 (n=42) 
was the Propofol based TIVA group.  These patients received Propofol and Remifentanil 
infusions for TIVA during the maintenance phase of anesthesia. Group 2 (n=41) was the 
Sevoflurane inhalation anesthetic group. These patients received Sevoflurane for the 
maintenance phase of anesthesia. Both group 1 and group 2 were induced with Fentanyl 
2-3 µg/kg, Propofol 1-2 µg/kg, and paralyzed with Rocuronium 0.6 mg/kg. Fresh gas 
flows of 2L/min were maintained on both groups as well as an [exhaled] carbon dioxide 
level of 35-45 mmHg. Both groups had blood drawn at standardized times, specifically 
preoperatively and postoperatively at the 24-hour mark.  
 Outcomes of the study done by Yan et al. (2018) (Appendix B, Table B-1) 
showed that VEGF-C levels increased from 133 (80-205) to 140 (92-250) in group 1 
(TIVA). There was a pre-post change value of 12 (-8-52) in this group. Group 2 had an 
increase in VEGF-C values from 105 (87-193) to 174 (111-281) and a pre-post change 
value of 3 (-3-47). The difference between groups’ VEGF-C values were not statistically 
significant preoperatively (p=0.729) or postoperatively (p=0.177). The pre-post change 
value, however, was statistically significant (p=0.008) in both groups. When comparing 
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TGF-b levels in group 1 preoperatively to postoperatively, those levels decreased from 
198 (100-304) to 176. There was a change value of 13 (-17-51) in the TIVA group. 
Group 2 experienced an increase in TGF-b levels when comparing preoperative values, 
197 (131-318), to postoperative values, 211 (109-308). This group had a change value of 
3 (-30 - 47). The levels of TGF-b were not statistically significant in the preoperative 
(p=0.721), postoperative (p=0.794), or pre-post changes (p=0.582), when comparing the 
two groups values. Group 1 had a recurrence free survival of 95% at the two-year mark. 
Group 2 had a recurrence free survival of 75% at the two-year mark. When comparing 
both groups, recurrence free survival was not statistically significant (p=0.221). 
 Utilizing the CASP questionnaire, (Appendix C, Table C-1), this study (Yan et 
al., 2018) has a clearly focused issue. All patients involved were randomized and both 
groups were similar at the start of the trial. Aside from the clinical intervention both 
groups were treated equally throughout the study. In addition, the healthcare members 
involved in measuring of the blood samples for the study were blinded as to which 
intervention the patient received. The results of this study can be applied to adult females 
undergoing breast cancer tumor removal that require general anesthesia. There are several 
limitations to this study. First, Propofol was used for induction for both groups. Propofol 
would have dissipated within 10-15 minutes after administration, but it is unclear if this 
affected the results of this study. Secondly, the number of patients enrolled in this study 
was small (n=83). Finally, this study was carried out in a single center.  
 The tri-center, prospective study by Ito et al. (2017) (Appendix A, Table A-2) 
looked at the effect of anesthetic technique (Propofol based TIVA versus Sevoflurane) on 
the immune response in patients undergoing breast cancer surgery in a day center or 
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hospital. A total of 37 patients who underwent breast cancer surgery, specifically, partial 
resection of the breast, sentinel lymph node biopsy with axillary lymph node dissection, 
or total mastectomy, were divided into two groups. Group 1 (n=21) was the Propofol 
based TIVA day center group.  These patients received Propofol, lidocaine, and Pethidine 
for TIVA during the maintenance phase of anesthesia. Group 2 (n=16), was the 
Sevoflurane with Propofol or Propofol with opioid TIVA hospitalized group. Seven 
patients (n=7) received TIVA of Propofol (1-3µg/mL with Remifentanil (0.25 µg/kg/min) 
for maintenance while Propofol (3µg/mL)	and Fentanyl (1-2µg/kg) were administered at 
induction. Four patients (n=4) received TIVA with Propofol (3µg/mL) for maintenance 
with Fentanyl (1-2µg/kg) and Propofol (2µg/kg) given at induction. Four patients (n=4) 
received Sevoflurane inhalation anesthetic (1.0-5.0%) and Remifentanil (0.25 µg/kg/min) 
drip for maintenance with Propofol (2µg/kg) and Fentanyl (1-2 µg/kg) given at induction. 
One patient (n=1) was maintained with Sevoflurane (1.0-5.0%) and given Propofol 
(3µg/mL) and Fentanyl (1-2 µg/kg) at induction. All patients in the hospitalized group 
were given Rocuronium (0.6 mg/kg) for paralysis and ventilated with a mixture of 1:2-3 
O2 and air. Both groups had blood drawn at standardized times, specifically, 
preoperatively, and postoperatively at the 24-hour mark.  
 Outcomes of the study done by Ito et al. (2017) (Appendix B, Table B-2) shows 
the median change values of NK Cell activity, CD4/8 T Cell Ratio, and IL-6 levels in the 
preoperative, postoperative, and 24-hours postoperatively. In Group 1 (day surgery TIVA 
group) median NK Cell activity preoperatively was 30.5± 9.2 and then fell to 29.0± 9.0. 
At the 24-hour mark the median NK Cell level rose to 32.0± 7.5. In Group 2 (hospitalized 
TIVA or Sevoflurane with opioid group) median NK cell activity was 24.5± 13.8. This 
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value rose to 31.0± 12.3 in the postoperative period and then fell to 25.0± 9.5 at the 24-
hour postoperative mark. In group 1 the CD4/8 T Cell Ratio median value rose steadily 
throughout all three time periods. Values started at 1.31± 0.32, increased to 1.53± 0.64, 
and rose to 1.67± 0.34 by the 24-hour postoperative time period. In Group 2 CD4/8 T 
Cell Ratio median values started at 1.63± 0.55, decreased to 1.23± 0.16, and then 
increased almost to baseline with a median value of 1.61± 0.68. In group 1 IL-6 median 
values started at 1.1± 0.5, fell to 1.0± 0.65, and then increased to 5.4± 1.35 in the 24-hour 
postoperative time frame. Group 2 showed an increasing trend of median IL-6 values 
across all three time periods. Initially median values were measured at 2.0± 1.94. In the 
postoperative period those values increased from 3.9± 2.95 postoperatively to 15.3± 7.15 
in the 24-hour postoperative period.  There was no statistical validity testing done with 
these values.  
 Utilizing the CASP questionnaire, (Appendix C, Table C-2), this study (Ito et al., 
2017)   has a clearly focused issue, patients were not randomized, both groups were 
similar at the start of the trial, and aside from the clinical intervention both groups were 
treated equally throughout the study. The healthcare members involved were not blinded 
to the intervention that the patient received. The results of this study might be applied to 
adult females undergoing breast cancer tumor removal that require general anesthesia. 
There are several limitations to this study. First, propofol was used for induction for both 
groups. Propofol would have dissipated within 10-15 minutes after administration, but it 
is unclear if this could have affected the results of this study. Secondly, the number of 
patients enrolled in this study is small (n=37). Third, this study did not clearly separate 
the two methods of delivery of anesthesia. Patients were grouped according to the setting 
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in which they received care, either hospitalized or a day surgery center, and not by the 
medication they received for maintenance of anesthesia.  
 The single center, randomized, retrospective analysis of an ongoing randomized 
clinical trial study by Buggy et al. (2018) (Appendix A, Table A-3) sought to determine if 
the inflammatory response would be less in breast cancer patients who received propofol 
based TIVA than those who received sevoflurane/ opioid based anesthesia for removal of 
cancerous breast tumors. The researchers measured the amounts of neutrophil-
lymphocyte ratio, white blood cell count, platelet count, and platelet-lymphocyte ratio. A 
total of 116 patients who underwent unilateral mastectomy, bilateral mastectomy, and 
lumpectomy with axillary node dissection that were enrolled in another ongoing 
randomized clinical trial were enrolled and divided into two groups. Group 1 (n=59) 
received propofol TIVA with a paravertebral nerve block. The paravertebral block was 
given as a one-time injection in the T1-T5 interspaces or an injection with thoracic 
epidural catheter placement, in the T2-T4 interspace, for continued postoperative pain 
management. Those that received an epidural catheter were administered a test dose of 
1.5% Lidocaine and 1:200,000 epinephrine and then followed with either bupivacaine 
0.5% or ropivacaine 0.5%. Those that were given multilevel injections were administered 
5mL of 0.75% bupivacaine. Postoperative pain was managed with either the 
paravertebral block or non-steroidal anti-inflammatory drugs (NSAID’s), morphine for 
intractable pain, and transitioned onto NSAID’s and paracetamol by the 24-hour 
postoperative mark. Group 2 (n=57) had sevoflurane with an opioid administered as the 
chosen anesthetic. For this group, anesthesia was induced using fentanyl 2-4 µg/kg and 
propofol 1-3 mg/kg. Sevoflurane and fentanyl were given to maintain heart rate and 
                                                                                                                                             
 
   
 
            33 
 
blood pressure within 20% of preoperative values. Morphine 0.1mg/kg was administered 
at the end of the surgery. Postoperative pain was managed with morphine or similar long 
acting opioid with a transition to paracetamol and NSAID by the 24-hour mark. Both 
groups had blood drawn at standardized times, specifically, preoperatively, and 
postoperatively. 
 Outcomes of the study done by Buggy et al. (2018) (Appendix B, Table B-3) 
shows the amounts of white blood cells, neutrophils, lymphocytes, platelets, neutrophil-
lymphocyte ratio, platelet-lymphocyte ratio, as well as the change in the neutrophil- 
lymphocyte ratio in the preoperative and postoperative period. In the preoperative period 
group 1 median white blood cell level was 7.4, while group 2 had a median white blood 
cell level of 7.2. When comparing these two median values there was no statistically 
significant difference. In group 1, the median neutrophil count was 4.7 whereas the 
median value for group 2 was 4.6 in the preoperative period. There was no statistically 
significant difference between the groups. In the preoperative period the median 
lymphocyte count was 2.0, while group 2 had a median value of 1.9. There was no 
statistically significant difference between the groups. Median levels of platelets in the 
preoperative period for group 1 was 292 and 265 for group 1. There was no statistically 
significant difference between these groups. The neutrophil-lymphocyte ratio median 
value in group 1 was 3.0 and 4.0 for group 2 and was not statistically significant 
different. The platelet-lymphocyte ratio median value was 142 for group 1 in the 
preoperative period, and was 148 for group 2, with no significant difference. 
In the postoperative period, group 1 and group 2 had a white blood cell count 
median value of 9.0. In the postoperative period, group 1 had a neutrophil count median 
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value of 6.4, whereas group 2 had a median value of 6.5. Group 1 had a median 
lymphocyte count of 1.8 and group 2 had a median lymphocyte count of 1.7. In the 
postoperative period group 1 had a median platelet value of 268. In the same time period, 
group 2 had a median platelet count of 237. The median neutrophil-lymphocyte ratio was 
significantly different (p=0.001) between the two groups (group 1: 3.0 versus group 2: 
4.0). Similarly, the change in median neutrophil-lymphocyte count from the preoperative 
time period to the postoperative time period was also significant (p=0.001), with group 1 
at 30% and group 2 at 82%. Finally, the median platelet-lymphocyte count in the 
postoperative period was 148 in group 1 and group 2 (Buggy et al., 2018).  
 Utilizing the CASP questionnaire, (Appendix C, Table C-3), this study Buggy et 
al. (2018) has a clearly focused issue. Patients were randomized and both groups were 
similar at the start of the trial. Aside from the clinical intervention, both groups were 
treated equally throughout the study. Whether the healthcare team was blinded to the 
treatment was not clear. The results of this study may be applied to adult females 
undergoing breast cancer tumor removal that require general anesthesia. There are several 
limitations to this study. First, propofol was used for induction for the sevoflurane group 
(group 2). Propofol would have dissipated within 10-15 minutes after administration, but 
it is unclear if this could have affected the results of this study. Secondly, blood samples 
postoperatively were taken at different times. All patients had all blood samples taken 
within 72 hours. However, when within the 72 hours the blood samples were taken 
varied.   
 The single-center, randomized, control trial by Oh et al. (2018) (Appendix A, 
Table A-4) compared the changes in amounts of cluster differentiation of regulatory T 
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cells in patients receiving propofol based TIVA or sevoflurane for breast cancer surgery. 
The researcher specifically measured the amounts of cluster differentiation enzyme 39 
(CD39) and cluster differentiation enzyme 73(CD73) on regulatory T cells as well as the 
median neutrophil-lymphocyte ratio. A total of 201 women who underwent breast cancer 
surgery were divided into two groups. Group 1 (n=99) was the propofol based TIVA 
group. This group received propofol TIVA with a target concentration of 40 µg/mL using 
a TCI device. Group 2 (n=102) was the sevoflurane group. This group received 
thoipental5mg/kg for induction. Maintenance anesthesia was achieved with sevoflurane 
inhalation anesthetic with a Bispectral Index (BIS) monitoring goal of 40-60 with 
remifentanil drip at a goal concentration of 5.0ng/mL. Both groups received lidocaine 
0.5mg/kg, rocuronium 0.6 mg/kg, ketorolac 0.5mg/kg, 0.03mg/kg neostigmine, and 
0.008mg/kg glycopyrrolate were given to both groups. Mean arterial pressure was 
maintained at 20% of baseline for both groups. Both groups had blood drawn at 
standardized times, specifically, preoperatively, postoperatively by the 1-hour mark, and 
again at the 24-hour mark.  
 Outcomes of the study done by Oh et al. (2018) (Appendix B, Table B-4) showed 
that expression of CD39 decreased overall in group 1 with values in the preoperative time 
period of 17.1%, 16.7%± 7.6% in the first hour postoperative, and 16.9% in the 24-hours 
postoperatively. CD39 was expressed 17.6% in the preoperative period, 16.5%± 7.9% in 
the first hour postoperatively, and returned to baseline (17.6%) within 24-hours 
postoperatively in group 2. Frequency of CD73 expression in group 1 was 19.4% in the 
preoperative period, 18.5% in the first hour postoperatively, and 19.2% in the 24-hours 
postoperatively. In group 2 frequency of CD73 expression was shown to increase across 
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all three time intervals. The preoperative value was 19.0%, with an increase in expression 
to 19.2%, and finally 19.6% by the 24-hour time interval. Although there was an increase 
in value, this was not statistically significant (p=0.658).  In group 1 the neutrophil-
lymphocyte ratio increased from 1.55 in the preoperative time period to 1.62 in the first 
hour postoperatively. The neutrophil-lymphocyte ratio was not measured at the 24-hour 
postoperative mark. In group 2 the neutrophil-lymphocyte ratio decreased from 1.76 
preoperatively to 1.68 at the 1-hour postoperative mark.  
 Utilizing the CASP questionnaire, (Appendix C, Table C-4), this study by Oh et 
al. (2018) has a clearly focused issue. All patients involved were randomized. Both 
groups were similar at the start of the trial and aside from the clinical intervention both 
groups were treated equally throughout the study.  The healthcare members involved in 
measuring the blood samples for the study were blinded as to which intervention the 
patient received. The results of this study can be applied to adult females undergoing 
breast cancer tumor removal that require general anesthesia. There are several limitations 
to this study. First, opioids and ketorolac that were used could potentially mask the pure 
effect of sevoflurane or propofol TIVA on the values measured.  Secondly, the use of 
immune markers, cluster differentiation 39 and 73, have not been proven to be a 
contributor to poor prognosis in humans as it has in animal studies (Antonioli et al., 
2013). Finally, this study was carried out in a single center.  
The single-center, randomized, double blind control trial by Kim et al. (2018) 
(Appendix A, Table A-5) sought to identify the effect of propofol TIVA versus 
sevoflurane on natural killer cells, cytotoxic T cells, IL-6 levels,IL-10, tumor necrosis 
factor-a (TNF-a), and apoptosis rates in patients undergoing surgery for breast cancer.  A 
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total of 44 women who underwent breast cancer surgery were divided into two groups. 
Group 1 (n=23) was the propofol based TIVA group. This group received propofol TIVA 
with a target concentration of 40 µg/mL using a TCI device. Group 2 (n=21) was the 
sevoflurane group. This group received thoipental 5mg/kg for induction. Maintenance 
anesthesia was achieved with sevoflurane inhalation anesthetic with a Bispectral Index 
(BIS) monitoring goal of 40-60 with remifentanil drip at a goal concentration of 
5.0ng/mL. Both groups received rocuronium 0.6 mg/kg, ketorolac 0.5mg/kg, 0.03mg/kg 
neostigmine, and 0.008mg/kg glycopyrrolate. Mean arterial pressure was maintained at 
20% of baseline or greater than 60mmHg for both groups. Both groups had blood drawn 
at standardized times, specifically, preoperatively, postoperatively by the 1-hour mark, 
and again at the 24-hour mark.  
 Outcomes of the study done by Kim et al., (2018) (Appendix B, Table B-5) 
showed that in group 1 median TNF-a decreased initially but rose overall with values in 
the preoperative time interval of 413 (390-470), 390 (390-430) at the one hour 
postoperative time interval, and 420 (390-430) by the 24-hour time interval. In group 2 
TNF-a levels followed the same pattern. Median values in the preoperative time interval 
were 404± 42, 400 (370-455) by the 1-hour postoperative mark, and then 417± 25 in the 
24-hour postoperative time frame. When comparing values of TNF-a in the preoperative 
period between group 1 and group 2 there was no statistical significance (p=0.175). 
Furthermore, there was no statistical significance when comparing TNF-a values 
between group 1 and group 2 in either postoperative time period with values of p=0.953 
at the 1-hour mark and p=0.958 at the 24-hour mark. Median levels of IL-6 in the 
preoperative time period were 90 for both groups 1 and 2. This was not statistically 
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significant with a value of p=0.524. By the one-hour postoperative mark, group 1 showed 
an increase in levels of IL-6 with median levels measuring 100 (90-100), while group 2 
values remained the same at 90 (90-100). By the 24-hour postoperative mark, Il-6 levels 
were 90 (90-100) for both groups. Median levels of Il-10 fell overall in group 1. In the 
preoperative time period median values of Il-10 were 490 (450-550). In the 1-hour 
postoperative time period median values remained the same, 490 (440-550). By the 24-
hour time frame the median IL-10 values fell to 470 (440-500) in group 1. In group 2 
median levels of IL-10 were 470 (445-525) preoperatively, 450 (435-520) at the 1-hour 
postoperative mark, and 470 (440-500) by the 24-hour postoperative mark. When 
comparing median values of IL-10 from group 1 to group 2, none of the values proved to 
be statistically significant with values of p=0.430, p=0.340, and p=960. 
 Utilizing the CASP questionnaire, (Appendix C, Table C-4), this study by Kim et 
al., (2018) has a clearly focused issue. All patients involved were randomized and both 
groups were similar at the start of the trial. Aside from the clinical intervention both 
groups were treated equally throughout the study.  The healthcare members involved in 
measuring of the blood samples for the study were double “blind” as to which 
intervention the patient received. The results of this study can be applied to adult females 
undergoing surgery to remove tumors caused by breast cancer. There are several 
limitations to this study. First, opioids and ketorolac that were used could potentially 
mask the pure effect of sevoflurane or propofol TIVA on the values measured. Secondly, 
there were very few women enrolled in the study (n=44). Lastly, this study was 
conducted at a single center. 
 Next, the summary and conclusions will be presented.  
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Summary and Conclusions 
 Metastasis of cancerous cells, specifically breast cancer cells, has been shown to 
increase chances of mortality.  According to the National Cancer Institute (2018) breast 
cancer survival was about 90% overall. Patients with distant metastasis had a survival 
rate of 27% and those with regional metastasis had an 85% survival rate. This shows that 
the more metastasis to distant areas, the lower the chance of survival of the patient 
(American Cancer Society, 2019). It is theorized that surgery can increase the amount of 
metastasis (Simmons et al., 2017). Therefore, limiting the amount of metastasis caused 
from breast cancer surgery would increase chances of survival. 
 Propofol is a phenol derivative that has been shown have several benefits that 
may aid in limiting immune dysfunction in breast cancer patients related to surgery. 
Propofol has been shown to limit NK dysfunction (Dilger, 2018) and aid in infiltration of 
the cancer cells by the immune system’s own NK cells and T lymphocytes (Buggy et al., 
2015). In addition, propofol has also been shown to have better long-term survival rates 
when compared to volatile agents such as sevoflurane (Jhanji et al., 2016). Sevoflurane, a 
volatile inhalation anesthetic, has been shown to have a higher cancer recurrence rates in 
breast cancer patients (Lee et al., 2016). When comparing sevoflurane to propofol base 
TIVA, patients who received sevoflurane had a lower survival rate at the one-year mark 
(Andreasson et. al., 2014). 
The purpose of this systematic review was to examine if Total Intravenous 
Anesthesia versus Sevoflurane is more efficacious in limiting the amounts of immune 
cells released during the perioperative period in breast cancer patients. A comprehensive 
literature review was completed using Pubmed, CINHAL, and Medline. This literature 
review focused on immunity, the immune system’s role in neoplasia and metastasis, 
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breast cancer, surgical approaches for breast cancer, and both propofol and sevoflurane’s 
effect on immunity involving breast cancer surgery. A theoretical framework was chosen 
to aid in the identification of eligible studies based on specific inclusion criteria. 
PRISMA was the theoretical framework chosen.  It is a 27-item checklist and four-phase 
flowchart (Altman, et al., 2009).  
 Individual study analysis was completed on the final five studies meeting criteria. 
Study specific data tables were created outlining key information from each study. Data 
outcome tables were created to determine the efficacy of propofol based TIVA and 
sevoflurane on limiting the amounts of immune cells released during the perioperative 
period in breast cancer patients. Next, critical appraisal of individual RCT’s was 
performed utilizing the Critical Appraisal Skills Programme (CASP) checklist. Last, a 
cross study analysis table was created to compare the types of immune cells released 
during the perioperative period.  
 There were several limitations noted when completing this systematic review. 
Some studies were not a randomized control study by design. Specifically, one study was 
a retrospective study of an ongoing randomized control trial and two studies were 
prospective control trials. The other two studies were randomized control trials. 
Secondly, two of the studies were not blinded. A third limitation is lack of consistence in 
which immune mediator was measured. Each study measured different immune cells and 
immune mediators; therefore there is a lack of congruency in results for comparison. 
Lastly, each study took blood samples at different times. This lack of consistency in time 
intervals for blood draws makes it difficult to draw definitive conclusions. 
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 The findings of this systematic review determined that propofol based TIVA 
increases recurrence free survival, however there is negligible differences in the immune 
response between propofol based TIVA and sevoflurane inhalation anesthetic for women 
undergoing surgery for breast cancer tumor excision.  




                                                                                                                                             
 
   
 
            42 
 
Recommendations and Implications for Advanced Nursing Practice 
 When weighing options in treatment for breast cancer, in many cases, the benefits 
of surgery outweigh the risks. Once the decision has been made to proceed with surgery, 
options for surgical approach are planned with the patient and surgeon in collaboration to 
choose the safest and most effective option. On the day of surgery, the anesthesia 
provider will meet the patient, assess them, and create an individualized anesthetic plan 
(Nagelhout & Plaus, 2018). The anesthesia provider will consider the patient’s 
comorbidities, airway anatomy, length and type of surgery, and postoperative pain 
management when selecting an anesthetic plan (Nagelhout & Plaus, 2018). However, 
with patients undergoing surgery for breast cancer, the anesthesia provider should also 
individualize a plan that will increase the patient’s chances of survival from breast 
cancer.  
 It is paramount that as anesthesia providers we always plan with the end in mind. 
In this case, the end should not be limited to the patients discharge from the recovery 
room. The end goal should be to increase chance of survival for the patient. Propofol has 
been shown to limit the amount of NK cell suppression in murine models (Bar-Yosef et 
al., 2003) and may increase the survival rate of patients undergoing breast cancer surgery 
at the two-year mark (Yan et al., 2018). However, as demonstrated in this systematic 
review, propofol may not have a noticeable effect on other immune mediators such as IL-
6, IL-10, neutrophils, and platelet levels. Sevoflurane has been shown to elicit an immune 
response, but its effects may not be significant. Continued research is needed in this area 
to determine which anesthetic choice will lead to better patient outcomes. In addition, 
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anesthesia providers should continue to be educated in immunology and anesthetic 
impact on breast cancer patients.  
 The overall recommendation from this systematic review is that anesthesia 
providers should continue to individualize an anesthetic plan that places the patient’s 
safety, comfort, and surgical success first. This systematic review has demonstrated that 
there is not a clear choice as to whether propofol based TIVA or sevoflurane will increase 
survivability and limit the immune response in this patient population. More research 
should be done in this area to identify if one method of anesthesia is superior to the other. 
Until such results are available, anesthesia providers should maximize survivability by 
limiting the surgical stress response in a way that also accounts for patient safety, pain 
management, and surgical success in breast cancer patients undergoing surgery for tumor 
removal.  
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Study Specific Data 
Sun, L., Wang, B.N., Yan, T., Zhang, G.H., & Zheng, H. (2018). Effects of propofol/remifentanil-based total intravenous anesthesia versus sevoflurane-based inhalational anesthesia 
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Sevoflurane with BIS 
values of 40-60. 
PROCEDURES 
Group 1 and 2 were 
induced with Fentanyl 2-
3µg/kg, Propofol 1-
2mg/kg, and 





45 mmHg, and a fresh 
gas flow of 2L/min 
oxygen.  
Fentanyl bolus’ given 
intraoperatively as 
needed in both groups. 
NSAIDS given for pain 
management. 
Group 1-Propofol and 
Remifentanil drips for 
maintenance phase. 
 
Group 2-Sevoflurane for 
maintenance phase.  
                                                                                                                                             





Study Specific Data 
 
Ito, M., Kadoya, T., Funaoka, Y.,Kawai, A., Kim, R., Wakisaka, M.,Y., Ohtani, S., & Okada, M. (2017). Differences in immune response to anesthetics used for day surgery versus 
hospitalization surgery for breast cancer patients. Clinical & Translational Medicine, 6(1), 1–8. Doi: 10.1186/s40169-017-0163-4 https://doi-org.ric.idm.oclc.org/10.1186/s40169-
017-0163-4 
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Patients were placed into 
groups based on hospital 
preference, and thus the 
anesthetic technique that 
coordinated with the chosen 
site. Blood levels were taken 
before, after, and 24 hours 
after surgery. 
Group 1- induction with 
1mg.kg Propofol and 35mg 
Pethidine. Maintenance was 
achieved via Propofol TIVA 
6-8mg/kg/h and 50-100mg of 
0.5% Lidocaine for 
localization of the area. 
Group 2- Selection of 
technique was at the 
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patients (n=4) received 
Propofol and Fentanyl for 
induction, Sevoflurane gas 
and Remifentanil drip for 
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received Propofol and 
Fentanyl for induction, 
Remifentanil/Fentanyl (TCI) 
TIVA for maintenance. Some 
patients(n=4) received 
Propofol and Fentanyl 
induction, Propofol and 
Fentanyl (TCI) TIVA for 
maintenance. Only one 
patient received Propofol and 
Fentanyl at induction and 
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Specifically 
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cell activity, CD4/8 
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Study Specific Data 
 
Buggy, D. J, Burns, D., Ní Eochagáin, A., Riedel, B., & Sessler, D. I. (2018). The effect of  
anaesthetic technique during primary breast cancer surgery on neutrophil-lymphocyte  
ratio, platelet-lymphocyte ratio and return to intended oncological therapy. Anaesthesia, 73(5), 603–611. https://doi-org.ric.idm.oclc.org/10.1111/anae.14207 
AIM/PURPOSE 
To determine if the 
inflammatory 
response would be 
less in breast 
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of the surgery 6-10mL 
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0.1mg/kg given at the 
end of surgery.  
PROCEDURES 
Patients were 
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anesthetic group. Charts 
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level of neutrophil-
lymphocyte ratio was 
noted. These levels 
were taken before and 
after surgery.  
 
 
                                                                                                                                             




Study Specific Data 
Kim, S.H., Lee, J.Y., Lee., S.H., Oh, C.S., Park, H.J., Piao, L., H., Seo, E.H., & Yoon, T.G. (2018b). Effect of Equipotent Doses of Propofol versus 
Sevoflurane Anesthesia on Regulatory T Cells after Breast Cancer Surgery. Anesthesiology, 129(5), 921–931. https://doi-
org.ric.idm.oclc.org/10.1097/ALN.0000000000002382 
AIM/PURPOSE The 
purpose of the study 
was to compare the 
amount of changes in 
cluster differentiation 
on regulatory T cells 
in patients receiving 
Propofol based TIVA 
and Sevoflurane for 




of enzyme 39 and 73 
on regulatory T cells. 
Amount of NK cells, 
cytotoxic T cells, 
cytokines, and 
neutrophil-to-
















201 women undergoing 
surgery for breast cancer. 
 







Patients were randomized 
into the two groups. 
 
Blood samples were 
obtained prior to 
induction and 24 hours 
postoperatively. 
 
Lidocaine was given, BIS 
monitoring was 
performed, and 
Rocuronium was given to 
all patients.  
 
PROCEDURES 
Patients were randomized 
into one of the two groups.  
 
Group 1-revieved Propofol 
(TCI) TIVA  with a goal of 
BIS monitoring 40-60 and 
MAP 20% of baseline or 
greater than 60mmHG for 
maintenance phase.  
 
Group 2 received Thiopental 
5mg/kg in addition to 
Rocuronium and Lidocaine 
for induction. For 
maintenance these patients 
were given Sevoflurane gas 
with a BIS monitoring 40-60 
and MAP 20% of baseline or 








                                                                                                                                             




Study Specific Data 
Kim, S.H., Lee, J. Y., Lee, S.H., Lim, J.A., Oh, C.S., Yoon, T.G., Yang, J. H., & Yoo, Y.B. (2018). The effect of propofol and sevoflurane on cancer cell, natural killer cell, and 
cytotoxic T lymphocyte function in patients undergoing breast cancer surgery: an in vitro analysis. BMC Cancer, 18, 1. https://doi-org.ric.idm.oclc.org/10.1186/s12885-018-4064-8 
AIM/PURPOSE 
The researchers 
sought to identify 
the effect of 
Propofol TIVA 
versus Sevoflurane 
on natural killer 
cells, cytotoxic T 
cells, and 
apoptosis rates in 
patients 
undergoing 
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for breast cancer.  
 









Patients were randomized 
into the two groups. 
Blood samples were 
obtained prior to 
induction, 1- hour 
postoperatively, and 24-
hours postoperatively. 
Anesthesia was induced. 
BIS monitoring was used 
on both groups. In 
addition to the given 
anesthetic, both groups 
received Ketorolac for 




Propofol (TCI) TIVA 
with a goal of BIS 40-60.  
 
Group 2- received 





was administered for 
maintenance with a goal 
of BIS 40-60.  
PROCEDURES 
Patients were randomized 
into one of the two groups.  
 
After induction group 
received Propofol (TCI) 
TIVA with a goal of BIS 
monitoring 40-60 and MAP 
20% of baseline or greater 
than 60mmHG for 
maintenance phase.  
 
Group 2- Received 
Sevoflurane gas with a BIS 
monitoring 40-60 and MAP 
20% of baseline or greater 
than 60mmHG. 
Neuromuscular blockade 
was reversed with 
neostigmine and 
glycopyrrolate at the 
termination of the anesthetic 
for both groups. 
                                                                                                                                             





Outcome Data Tables 
 
Sun, L., Wang, B.N., Yan, T., Zhang, G.H., & Zheng, H. (2018). Effects of propofol/remifentanil-based total intravenous anesthesia versus sevoflurane-based inhalational 




Group 1-TIVA Group 2-Sevoflurane P Value 
     VEGF-C 
 
133 (80-205) 105 (87-193) p=0.729 
     TGF-b 198 (100-304) 197 (131-318) p=0.721 
Postoperative Values (24 hours) 
     VEGF-C 140 (92-250) 174 (111-281) p=0.177 
      TGF-b 176 (116-361) 211 (109-308) p=0.794 
Pre-Post Changes 
     VEGF-C 12 (-8-52) 50 (21-108) p=0.008 
      TGF-b 13 (-17-51) 3(-30-47) p=0.582 
Recurrence Free 
Survival at 24 
months 
postoperatively  
95% 75% p=0.221 
 
 
                                                                                                                                             





Outcome Data Tables 
 
Ito, M., Kadoya, T., Funaoka, Y.,Kawai, A., Kim, R., Wakisaka, M.,Y., Ohtani, S., & Okada, M. (2017). Differences in immune response to anesthetics used for day surgery 
versus hospitalization surgery for breast cancer patients. Clinical & Translational Medicine, 6(1), 1–8. Doi: 10.1186/s40169-017-0163-4 https://doi-
org.ric.idm.oclc.org/10.1186/s40169-017-0163-4 
Changes in Median 
Values 
Preoperatively 
Group 1-Day surgery, Lidocaine/Propofol/Pethidine 
(TIVA) (n=21) 
Group 2-Hospitalized, Sevoflurane/Propofol, systemic-opioid-based 
(n=16) 
     NK Cell   
     Activity 
30.5 ± 9.2  
 
24.5 ± 13.8 
 
     CD4/8 T Cell  
     Ratio 
 1.31 ± 0.32  
 
1.63 ± 0.55 
 
     IL6 1.1 ± 0.5  
 
2.0 ± 1.94 
Changes in Median Values Postoperatively 
     NK Cell  
     Activity 
29.0 ± 9.0 31.0 ± 12.3 
     CD4/8 T Cell  
     Ratio 
1.53 ± 0.64 1.23 ± 0.16 
     IL-6 1.0 ± 0.65 3.9 ± 2.95 
Changes in Median Values (24 hours) 
     NK Cell  
     Activity 
32.0 ± 7.5  25.0 ± 9.5 
     CD4/8 T Cell  
     Ratio 
1.67 ± 0.34 1.61 ± 0.68  
     IL-6 5.4 ± 1.35  15.3 ± 7.15  
                                                                                                                                             






Outcome Data Tables 
 
Buggy, D. J, Burns, D., Ní Eochagáin, A., Riedel, B., & Sessler, D. I. (2018). The effect of  
anaesthetic technique during primary breast cancer surgery on neutrophil-lymphocyte  
ratio, platelet-lymphocyte ratio and return to intended oncological therapy. Anaesthesia, 73(5), 603–611. https://doi-org.ric.idm.oclc.org/10.1111/anae.14207 
Preoperative Median 
Values 
Group 1-Propofol/Paravertebral TIVA 
(n=59) 
Group 2-Sevoflurane/Opioid  
(n=57) 
P Value 
    White Cell 
 
7.4 7.2 p=0.850 
    Neutrophil 4.7 4.6 p=0.825 
    Lymphocyte 2.0 1.9 p=0.915 
    Platelets 292 265 p=0.565 
    Neutrophil-   
    Lymphocyte  
    Ratio 
3.0 4.0 p=0.850 
    Platelet- 
    Lymphocyte   
    Ratio      
142 148 p=0.640 
Postoperative Median 
Values (Within 72 hours) 
   
    White Cell  
    ×109.l−1 
9.0 9.0 p=0.900 
     Neutrophil 
    ×109.l−1 
6.4 6.5 p=0.885 
     Lymphocyte 
     ×109.l−1 
1.8 1.7 p=0.860 
     Platelets 
     ×109.l−1 
268 237 p=0.610 
     Neutrophil- 
     Lymphocyte  
     Ratio 
3.0 4.0 p=0.001 
    Change in  
    Neutrophil- 
    Lymphocyte  
    Ratio 
30% 81% p=0.001 
    Platelet-Lymphocyte  
   Ratio 
148 148 p=0.885 
                                                                                                                                             





Outcome Data Tables 
 
Kim, S.H., Lee, J.Y., Lee., S.H., Oh, C.S., Park, H.J., Piao, L., H., Seo, E.H., & Yoon, T.G. (2018b). Effect of Equipotent Doses of 






Preoperative Value 1-Hour Post Procedure 24 Hours Post 
Procedure 
P Value 
     Frequency of  
     CD39  





p = 0.680 
 
     Frequency of  
     CD73  
     Expression 
19.4% 18.5% 19.2% p = 0.658 
 
     Median  
     Value:  
     Neutrophil- 
     Lymphocyte   
     Ratio      
1.55 1.62  p=0.202 
Group 2- Sevoflurane  
N=102 
    
     Frequency of  
     CD39  
     Expression 
17.6% 16.5 ± 7.9% 
 
17.6% p = 0.680 
 
     Frequency of  
     CD73  
     Expression 
19.0% 19.2% 19.6% p = 0.658 
 
     Median  
     Value: 
     Neutrophil- 
     Lymphocyte  
     Ratio 
1.76 1.68  p=0.883 
 
                                                                                                                                             





Outcome Data Tables 
 
Kim, S.H., Lee, J. Y., Lee, S.H., Lim, J.A., Oh, C.S., Yoon, T.G., Yang, J. H., & Yoo, Y.B.  
(2018a). The effect of propofol and sevoflurane on cancer cell, natural killer cell, and cytotoxic T lymphocyte function in patients undergoing breast cancer surgery: an in vitro 











































417 ± 25 
 
p=0.958 
IL-6 90 (80-100) 90 (90-95) p=0.542 100 (90-100) 90 (90-100) p=0.511 90 (90-100) 90 (90-
100) 
p=0.774 
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intravenous anesthesia versus sevoflurane-based inhalational anesthesia on the release of VEGF-C and TGF-β and 
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     1. Did the trial address a clearly focused issue?  X   
     2. Was the assignment of patients to treatments             
randomized?  
X   
     3. Were all of the patients who entered the trial 
properly     accounted for at its conclusion?  
X   
     4. Were patients, health workers, and study personnel 
“blind” to treatment?  
X   
     5. Were the groups similar at the start of the trial?  X   
     6. Aside from the experimental intervention, were the 
groups treated equally?  
X   
B. What are the results?  
     7. How large was the treatment effect?  83 female patients undergoing surgery for 
breast cancer removal 
     8. How precise was the estimate of the treatment 
effect?  
Significantly higher amounts of VEGF-C 
released in Sevoflurane group, minor 
difference in recurrence free survival 
between groups. 
C. Will the Results Help Locally? YES CAN’T 
TELL 
NO 
     9. Can the results be applied in your context?  X   
     10. Were all clinically important outcomes 
considered?  
X   
     11. Are the benefits worth the harms and costs?  X   
                                                                                                                                             
 
   
 









Ito, M., Kadoya, T., Funaoka, Y.,Kawai, A., Kim, R., Wakisaka, M.,Y., Ohtani, S., & Okada, M. (2017). 
Differences in immune response to anesthetics used for day surgery versus hospitalization surgery for breast 
cancer patients. Clinical & Translational Medicine, 6(1), 1–8. Doi: 10.1186/s40169-017-0163-4 https://doi-
org.ric.idm.oclc.org/10.1186/s40169-017-0163-4 
 





     1. Did the trial address a clearly focused issue?  X   
     2. Was the assignment of patients to treatments        
randomized?  
  X 
     3. Were all of the patients who entered the trial 
properly accounted for at its conclusion?  
X   
     4. Were patients, health workers, and study 
personnel “blind” to treatment?  
  X 
     5. Were the groups similar at the start of the trial?  X   
     6. Aside from the experimental intervention, were 
the groups treated equally?  
X   
B. What are the results?  
     7. How large was the treatment effect?  37 female patients undergoing 
surgery for breast cancer removal 
     8. How precise was the estimate of the treatment 
effect?  
No difference between the two 
groups 
C. Will the Results Help Locally? YES CAN’T 
TELL 
NO 
     9. Can the results be applied in your context?   X  
     10. Were all clinically important outcomes    
considered?  
X   
     11. Are the benefits worth the harms and costs?  X   
                                                                                                                                             
 
   
 









Buggy, D. J, Burns, D., Ní Eochagáin, A., Riedel, B., & Sessler, D. I. (2018). The effect of anaesthetic technique 
during primary breast cancer surgery on neutrophil-lymphocyte ratio, platelet-lymphocyte ratio and return to 
intended oncological therapy. Anaesthesia, 73(5), 603–611. https://doi-org.ric.idm.oclc.org/10.1111/anae.14207 
 





     1. Did the trial address a clearly focused issue?  X   
     2. Was the assignment of patients to treatments        
randomized?  
X   
     3. Were all of the patients who entered the trial 
properly accounted for at its conclusion?  
X   
     4. Were patients, health workers, and study personnel 
“blind” to treatment?  
 X  
     5. Were the groups similar at the start of the trial?  X   
     6. Aside from the experimental intervention, were 
the groups treated equally?  
X   
B. What are the results?  
     7. How large was the treatment effect?  201 female patients undergoing 
surgery for breast cancer removal 
     8. How precise was the estimate of the treatment 
effect?  
Changes in amounts of immune cells 
released were similar with propofol 
and sevoflurane. 
 
C. Will the Results Help Locally? YES CAN’T 
TELL 
NO 
     9. Can the results be applied in your context?  X   
     10. Were all clinically important outcomes 
considered?  
X   
     11. Are the benefits worth the harms and costs?  X   
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https://doiorg.ric.idm.oclc.org/10.1097/ALN.0000000000002382 





     1. Did the trial address a clearly focused issue?  X   
     2. Was the assignment of patients to treatments        
randomized?  
X   
     3. Were all of the patients who entered the trial 
properly accounted for at its conclusion?  
X   
     4. Were patients, health workers, and study 
personnel “blind” to treatment?  
X   
     5. Were the groups similar at the start of the trial?  X   
     6. Aside from the experimental intervention, were 
the groups treated equally?  
X   
B. What are the results?  
     7. How large was the treatment effect?  116 female patients undergoing 
surgery for breast cancer removal 
     8. How precise was the estimate of the treatment 
effect?  
Propofol-paravertebral TIVA 
attenuated the postoperative increase 
in the neutrophil-lymphocyte ratio. 
C. Will the Results Help Locally? YES CAN’T 
TELL 
NO 
     9. Can the results be applied in your context?  X   
     10. Were all clinically important outcomes 
considered?  
X   
     11. Are the benefits worth the harms and costs?  X   
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Kim, S.H., Lee, J. Y., Lee, S.H., Lim, J.A., Oh, C.S., Yoon, T.G., Yang, J. H., & Yoo, Y.B.  
(2018a). The effect of propofol and sevoflurane on cancer cell, natural killer cell, and cytotoxic T 
lymphocyte function in patients undergoing breast cancer surgery: an in vitro analysis. BMC Cancer, 
18, 1. https://doi-org.ric.idm.oclc.org/10.1186/s12885-018-4064-8 





     1. Did the trial address a clearly focused issue?  X   
     2. Was the assignment of patients to treatments        
randomized?  
X   
     3. Were all of the patients who entered the trial 
properly accounted for at its conclusion?  
X   
     4. Were patients, health workers, and study personnel 
“blind” to treatment?  
X   
     5. Were the groups similar at the start of the trial?  X   
     6. Aside from the experimental intervention, were the 
groups treated equally?  
X   
B. What are the results?  
     7. How large was the treatment effect?  44 female patients undergoing surgery 
for breast cancer removal 
     8. How precise was the estimate of the treatment 
effect?  
No difference in NK cell and CTL 
counts between groups.  
C. Will the Results Help Locally? YES CAN’T 
TELL 
NO 
     9. Can the results be applied in your context?  X   
     10. Were all clinically important outcomes considered?  X   
     11. Are the benefits worth the harms and costs?  X   
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Appendix D 
Cross Study Analysis 
AUTHOR / YEAR COMPARISONS OR 





(Sun et al., 2018) 
 
VEGF-C, TGF-b Levels, 
Recurrence Free Survival 
 
Group 1: TIVA 
T0: Prior to procedure 
T1: 24 hours post procedure 
T0/T1: Comparison 
T3: 2 Year Recurrence Free 
Survival 
 
Group 2: Sevoflurane 
T0: Prior to procedure 
T1: 24 hours post procedure 
T0/T1: Comparison 





Group 1: TIVA 
VEGF-C levels increased from 133 to 
140 in the preoperative (T0) to 
postoperative time (T1). There was a 
pre/post changes value of 12 when 
comparing the preoperative value to 
the postoperative value. 
Group 2: Sevoflurane 
There was an increase in VEGF-C 
levels from 105 to 174 in preoperative 
(T0) to postoperative values (T1). 
There was a pre-post changes value of 
50 when comparing the preoperative 
value to postoperative value. 
TGF-b 
Group 1: TIVA 
TGF-b values decreased from 198 to 
176 from T0 to T1. There was a 
change of 13 when comparing T0 to 
T1.  
Group 2: Sevoflurane 
TGF-b values increased from 197 (T0) 
to 211 (T1). There was a change value 
of 3 when comparing T0 to T1.  
 
Recurrence Free Survival 
Group 1: TIVA 
Two patients experienced a 
recurrence of their cancer. There 
was a recurrence free survival 
value of 95% at the two-year 
mark in this group. 
Group 2: Sevoflurane 
Six patients had recurrence of 
their cancer in this group. There 
was a 78% recurrence free 
survival rate in this group.  
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Study 2 
(Ito et al., 2017) 
Changes in NK Cell activity, 
Changes in CD4/8 T Cell Ratio, 
Changes in IL-6 Levels 
 





T2: 24 hours postoperative  
 









Changes in NK Cell Activity 
Group 1: Day surgery, 
Lidocaine/Propofol/Pethidine 
(TIVA) 
There was a slight decrease in 
values from 30.5 ± 9.2  
(T0) to 29.0 ± 9.0 (T1). Values 
then increased slightly to 
32.0 ± 7.5 (T2). 
Group 2: Sevoflurane 
Values stayed fairly steady through 
all time periods, 24.5 ± 13.8 (T0), 
31.0 ± 12.3 (T1), and 25.0 ± 9.5 
 
Changes in CD4/8 T Cell Ratio 
Group 1: Day surgery, 
Lidocaine/Propofol/Pethidine 
(TIVA) 
The changes in median value of 
CD4/8 T Cell ratio increased over 
all time periods. The median value 
at T0 was 1.31 ± 0.32 which 
increased to 1.53 ± 0.64 (T1), and  
1.67 ± 0.34 (T2). 
Group 2: Sevoflurane 
The changes in CD4/8 T Cell 
median values decreased from 
1.63 ± 0.55 (T0) to 1.23 ± 0.16 
(T1), and then returned to close to 
baseline 1.61 ± 0.68 at T2.  
 
Changes in IL-6 Levels 
Group 1: Day surgery, 
Lidocaine/Propofol/Pethidine 
(TIVA) 
Levels remained fairly 
unchanged, 1.1 ± 0.5 (T0) to  
1.0 ± 0.65 (T1), between the first 
time intervals. There was a sharp 
increase in levels at T2 with a 
median value of 5.4 ± 1.35. 
Group 2: Sevoflurane 
There was an increase in median 
levels from 2.0 ± 1.94 (T0) to  
3.9 ± 2.95 (T1). A larger increase 
occurred with a median level of  
15.3 ± 7.15 at T2.  
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Study 3 
(Buggy et al., 2018) 
Amount of White Cells, 
Neutrophils, Lymphocytes, 
Platelets, as well as the 
Neutrophil-Lymphocyte Ratio, 





Propofol/Paravertebral TIVA  
T0: Preoperative 
T1: 24 hours postoperative 
 
Group 2: Sevoflurane/Opioid 
T0: Preoperative 




White Cell Levels 
Group 1: Propofol/Paravertebral 
TIVA  
There was an increase in white cell 
levels from 7.4 (T0) to 9.0 (T1) 
Group 2: Sevoflurane/Opioid 
There was an increase in white cell 
levels from 7.2 (T0) to 9.0 (T1) 
 
Neutrophils 
Group 1: Propofol/Paravertebral 
TIVA 
There was an increase from 4.7 (T0) to 
6.4 (T1). 
Group 2: Sevoflurane/Opioid 




Group 1: Propofol/Paravertebral 
TIVA 
Levels slightly decreased from 2.0 (T0) 
to 1.8 (T1).  
Group 2: Sevoflurane/Opioid 
There was a slight decrease from 1.9 
(T0) to 1.7 (T1). 
 
Platelets 
Group 1: Propofol/Paravertebral 
TIVA 
Levels decreased from 292 (T0) to 268 
(T1). 
Group 2: Sevoflurane/Opioid 
There was a decrease from 265 (T0) to 
237 (T1). 
Platelet-Lymphocyte Ratio 
Group 1: Propofol/Paravertebral 
TIVA 
There was a slight increase from 
142 (T0) to 148 (T1).  
 
Group 2: Sevoflurane/Opioid 
The value remained the same for 





Group 1: Propofol/Paravertebral 
TIVA 
The value remained unchanged for 
both time intervals with a value of 
3.0. 
Group 2: Sevoflurane/Opioid 
The value remained unchanged at 
both time intervals with a value of 
4.0 
 
Change in Neutrophil-Lymphocyte 
Ratio 
Group 1: Propofol/Paravertebral 
TIVA 
There was a change in the 
Neutrophil-Lymphocyte Ratio of 
30% for group 1.  
Group 2: Sevoflurane/Opioid 
There was a change in the 
Neutrophil-Lymphocyte Ratio of 
81%in group 2.  
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Study 4 
(Kim et al., 2018b) 
Frequency of CD39 Expression, 
Frequency of CD73 Expression, 
and Median Values of 
Neutrophil-Lymphocyte Ratio 
 
Group 1: Propofol (TIVA) 
T0: Preoperative 
T1:1-hour postoperative 
T2: 24 hours postoperative  
 
Group 2: Sevoflurane 
T0: Preoperative 
T1: 1-hour postoperative 
T2: 24 hours postoperative  
 
 
Frequency of CD39 Expression 
Group 1: Propofol (TIVA)  
 There was a decrease in 
expression with values decreasing 
from 17.1% (T0), 16.7 ± 7.6% 
(T1), to 16.9% (T2). 
Group 2: Sevoflurane 
There was a decrease in expression 
from 17.6% (T0) to 16.5 ± 7.9% 
(T1). Expression returned to 
baseline of 17.6% at T2.  
 
Frequency of CD73 Expression 
Group 1: Propofol (TIVA) 
There was a decrease in expression 
from 19.4% (T0) to 18.5% (T1). 
Expression then increased to 
19.2% (T2).  
Group 2: Sevoflurane/Opioid 
Expression levels remained fairly 
steady with expression values of 




Median Values of Neutrophil-
Lymphocyte Ratio 
Group 1: Propofol (TIVA)  
 Median values remained fairly 
unchanged with a value of 1.55 
at T0 and 1.62 at T1. 
Group 2: Sevoflurane 
Median Values decreased from 
1.76 at T0 to 1.68 at T1.  
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Study 5 
(Kim et al., 2018a) 
Amount of TNF-a, IL-6, and IL-
10 
 
Group1: Propofol (TIVA) 
T0: Preoperative 
T1: 1-hour postoperative 
T2: 24 hours postoperative 
 
Group 2: Sevoflurane 
T0: Preoperative 
T1: 1-hour postoperative 
T2: 24 hours postoperative 
 
 
Amount of IL-6 
Group 1: Propofol (TIVA)  
The amount increased from 90 
(T0) to 100 (T1) and then returned 
to baseline of 90 at T2.  
Group 2: Sevoflurane 
The amount remained unchanged 
for all time periods with a value of 
90 (T0, T1, and T2).  
 
Amount of IL-10 
Group 1: Propofol (TIVA) 
The amount remained unchanged 
at T0 and T1 with a value of 490, 
then decreased to 470 at T2.  
Group 2: Sevoflurane/Opioid 
The amount decreased from 470 
(T0) to 450 (T1) and then returned 
to baseline value of 470 at T2.  
 
Amount of TNF-a 
Group 1: Propofol (TIVA)  
The amount decreased from 410 
(T0) to 390 (T1) and then 
increased to 420 (T2). 
Group 2: Sevoflurane 
The amount decreased from 
404 ± 42 (T0) to 400 (T1) and 
then sharply increased to 417 ± 
25 at T2.  
 
 
 
 
 
 
 
 
 
 
 
 
